Previous close | 924.00 |
Open | 924.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 924.00 - 925.00 |
52-week range | 9.25 - 948.05 |
Volume | |
Avg. volume | 1,679,225 |
Market cap | 1.234B |
Beta (5Y monthly) | 1.47 |
PE ratio (TTM) | 41.48 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.08 (0.82%) |
Ex-dividend date | 02 Dec 2021 |
1y target est | N/A |
Shareholders in Clinigen, whose top investor is hedge fund Elliott, will receive 925 pence per share in cash, up from a December bid of 883 pence apiece. New York-based Elliott, which had been raising its holding in Clinigen over the past few months amid reports it was seeking a break-up of the group, owns a 10.5% stake in the British company, according to Refintiv Eikon data. The latest offer by Triley Bidco, a newly created company indirectly owned by Triton Funds, is final and is recommended by the Clinigen board, the companies said in a joint statement.
Clinigen on Wednesday agreed to be bought by UK-based Triton Investment Management in a deal that values the pharmaceutical services group at about 1.2 billion pounds ($1.6 billion), making it the latest British company to go private. Last week, Clinigen confirmed advanced talks with the private-equity firm over a possible deal. Pressure has built on the company since Elliott Management raised its stake in recent weeks amid reports the activist investor was seeking to break up Clinigen.
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...